Request Demo

Last update 08 May 2025

Propatyl Nitrate

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Propatyl nitrate (USAN), Propatylnitrate, Propatylnitrate (INN)

+ [7]

Target-

Action

donors

Mechanism

Nitric oxide donors

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Angina Pectoris

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC6H11N3O9

InChIKeyYZZCJYJBCUJISI-UHFFFAOYSA-N

CAS Registry2921-92-8

Clinical Trials associated with Propatyl Nitrate

NCT02315976

/ CompletedPhase 4IIT

Avaliação de episódios Agudos na Angina Pectoris crônica estável: Abordagem clínico-laboratorial do Uso do Vasodilatador Coronariano Propatilnitrato.

This is an open, self-paired study of 200 patients with heart failure who have a diagnosis of chronic stable angina pectoris, who will be treated for 30 days with propatyl nitrate (10mg) . Treatment regimen is 3 sublingual tablets per day, at 8:00 AM, 2:00 PM, and 8:00 PM. The study will include three visits the patient to the study center: Pretreatment / Assessment 1, Assessment 2 after 15 days of treatment, and the Assessment 3 after 30 days of treatment. At each visit, data will be collected on the medical history, physical examination and vital signs, and evaluation of episodes of angina pectoris, as well as the laboratory evaluation of adverse events and the use of concomitant medications.

Start Date01 Apr 2014

Sponsor / Collaborator

Fundação Educacional Serra dos Órgãos

ACTRN12608000546358

/ CompletedNot Applicable

Phase III-B, open randomized study to evaluate the coronary vasodilator effect of a generic or reference propatylnitrate formulation administrated in sublingual route during coronariography

Start Date15 Jan 2009

Sponsor / Collaborator

Eurofarma Laboratórios SA

100 Clinical Results associated with Propatyl Nitrate

100 Translational Medicine associated with Propatyl Nitrate

100 Patents (Medical) associated with Propatyl Nitrate

116

Literatures (Medical) associated with Propatyl Nitrate

01 Mar 2025·The Journal of Allergy and Clinical Immunology: In Practice

Fertility Outcomes in Women With Asthma: A Danish Nationwide Cohort Study

Article

Author: Pinborg, Anja ; Ali, Zarqa ; Ulrik, Charlotte Suppli ; Lidegaard, Øjvind ; Mikkelsen, Anders P ; Hansen, Anne Vejen ; Håkansson, Kjell E J

BACKGROUNDAsthma is common among women of reproductive age. Prior studies have revealed an association between asthma and fertility by reporting prolonged time to pregnancy and lower fecundability.OBJECTIVETo investigate fertility in women treated with asthma medication compared with women without asthma.METHODSAll women born between 1976 and 1999, who were living in Denmark on their 18th birthday, were followed from 1994 to 2017. Asthma was defined as repeated fulfillment of asthma medication prescriptions, and severity was classified according to the Global Initiative for Asthma guidelines (GINA). Outcome was fertility treatment in women with asthma compared with women without asthma, applying a Cox regression model adjusted for age, calendar year, and education.RESULTSThe cohort comprised 765,606 women followed up, starting on their 18th birthday, for a median time of 10.8 years (interquartile range: 5.3-17.5 years). Compared with women without asthma, women with asthma had a comparable proportion giving birth during follow-up, slightly more experienced fetal loss (17.0% vs 15.8%), and required fertility treatment (5.6% vs 5.0%). The risk of fertility treatment was significantly higher in women with asthma (hazard ratio [HR]: 1.10, 95% confidence interval [CI]: 1.07-1.14). Women on GINA treatment steps 4 and 5 had an even higher risk of fertility treatment (HR: 1.59, 95% CI: 1.41-1.80) and, likewise, women with ≥3 prior exacerbations of asthma (HR: 1.36, 95% CI: 1.17-1.58).CONCLUSIONWomen with asthma have an increased use of fertility treatment, which correlates with asthma severity and exacerbation burden. However, asthma does not seem to affect number of live births.

01 Jan 2025·Pediatric Pulmonology

A cost‐utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed‐dose therapy in patients aged 12 years or more with uncontrolled asthma

Article

Author: Sossa‐Briceño, Monica P. ; Castro‐Rodriguez, Jose A. ; Rodríguez‐Martínez, Carlos E.

AbstractObjectivesA significant percentage of patients with asthma appear to benefit from the addition of long‐acting β2‐agonists (LABAs) to ICS to achieve better control of their disease. The aim of the present study was to determine the cost‐utility of single inhaler combination inhaled ICS/LABAs as both maintenance and reliever (SMART) versus remaining at the same treatment step with fixed‐dose ICS–LABA maintenance with a short‐acting β2‐agonist (SABA) as reliever in patients aged 12 years or more with uncontrolled asthma.MethodsA Markov‐type model was developed to estimate the costs and health outcomes of a simulated cohort of patients aged 12 years or more with uncontrolled asthma treated for 12 months. The effectiveness data and transition probabilities were obtained from a recent meta‐analysis. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The main outcome was the variable “quality‐adjusted life‐years” (QALYs).ResultsThe base‐case analysis showed that compared with remaining at the same GINA treatment step with ICS/LABA maintenance plus SABA reliever, ICS/LABAs as SMART was associated with lower costs, US$2,906.92 versus $4,462.02 average cost per patient, and the greatest gain in QALYs, 0.8540 versus 0.8258 QALYs on average per patient, thus leading to dominance.ConclusionsCompared with remaining at the same GINA treatment step with ICS/LABA maintenance plus SABA reliever, ICS/LABAs as SMART is more cost‐effective in patients aged 12 years or more with uncontrolled asthma. This is because ICS/LABAs as SMART showed a greater gain in QALYs at lower total treatment costs.

01 Jun 2024·The Lancet Regional Health - Europe

Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)

Article

Author: Vadel, Jade ; Delaisi, Bertrand ; Gouverneur, Amandine ; Collin, Cédric ; Demoly, Pascal ; Girard, Laurence ; Scurati, Silvia ; Bergmann, Jean-François ; Molimard, Mathieu ; Devillier, Philippe

BackgroundThe only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of liquid sublingual immunotherapy (SLIT-liquid) on asthma onset and evolution in AR patients.MethodsAn analysis with propensity score weighting was performed using the EfficAPSI cohort, comparing patients dispensed SLIT-liquid with patients dispensed AR symptomatic medication with no history of AIT (controls). Index date corresponded to the first dispensation of either treatment. The sensitive definition of asthma event considered the first asthma drug dispensation, hospitalisation or long-term disease (LTD) for asthma, the specific one omitted drug dispensation and the combined one considered omalizumab or three ICS ± LABA dispensation, hospitalisation or LTD. In patients with pre-existing asthma, the GINA treatment step-up evolution was analysed.FindingsIn this cohort including 112,492 SLIT-liquid and 333,082 controls, SLIT-liquid exposure was associated with a significant lower risk of asthma onset vs. control, according to all definitions (combined: HR [95% CI] = 0.62 [0.60-0.63], sensitive: 0.77 [0.76-0.78], and specific: 0.67 [0.61-0.72]). Exposure to SLIT was associated with a one-third reduction in GINA step-up regardless baseline steps.InterpretationIn this national RWS with the largest number of person-years of follow-up to date in the field of AIT, SLIT-liquid was associated with a significant reduction in the risk of asthma onset or worsening. The use of three definitions (sensitive or specific) and GINA step-up reinforced the rigorous methodology, substantiating SLIT-liquid evidence as a causal treatment option for patients with respiratory allergies.FundingStallergenes Greer.

100 Deals associated with Propatyl Nitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D05627	Propatyl Nitrate	C01DA07	DB13255

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angina Pectoris	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis